Roivant Sciences Ltd.

NasdaqGS:ROIV Stock Report

Market Cap: US$9.0b

Roivant Sciences Balance Sheet Health

Financial Health criteria checks 3/6

Roivant Sciences has a total shareholder equity of $6.6B and total debt of $449.0M, which brings its debt-to-equity ratio to 6.8%. Its total assets and total liabilities are $7.3B and $728.1M respectively.

Key information

6.8%

Debt to equity ratio

US$449.04m

Debt

Interest coverage ration/a
CashUS$6.67b
EquityUS$6.58b
Total liabilitiesUS$728.10m
Total assetsUS$7.31b

Recent financial health updates

No updates

Recent updates

Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success

Mar 18

We Believe Roivant Sciences' (NASDAQ:ROIV) Earnings Are A Poor Guide For Its Profitability

Feb 21
We Believe Roivant Sciences' (NASDAQ:ROIV) Earnings Are A Poor Guide For Its Profitability

These Analysts Just Made A Decent Downgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) EPS Forecasts

Nov 15
These Analysts Just Made A Decent Downgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) EPS Forecasts

Are Investors Undervaluing Roivant Sciences Ltd. (NASDAQ:ROIV) By 21%?

Apr 26
Are Investors Undervaluing Roivant Sciences Ltd. (NASDAQ:ROIV) By 21%?

Broker Revenue Forecasts For Roivant Sciences Ltd. (NASDAQ:ROIV) Are Surging Higher

Nov 22
Broker Revenue Forecasts For Roivant Sciences Ltd. (NASDAQ:ROIV) Are Surging Higher

Newsflash: Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Have Been Trimming Their Revenue Forecasts

Sep 29
Newsflash: Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Have Been Trimming Their Revenue Forecasts

Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Are Reducing Their Forecasts For This Year

Aug 21
Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Are Reducing Their Forecasts For This Year

Roivant Sciences GAAP EPS of -$0.48, revenue of $4.32M

Aug 15

An Intrinsic Calculation For Roivant Sciences Ltd. (NASDAQ:ROIV) Suggests It's 22% Undervalued

Aug 12
An Intrinsic Calculation For Roivant Sciences Ltd. (NASDAQ:ROIV) Suggests It's 22% Undervalued

Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Jun 30
Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Financial Position Analysis

Short Term Liabilities: ROIV's short term assets ($6.8B) exceed its short term liabilities ($244.9M).

Long Term Liabilities: ROIV's short term assets ($6.8B) exceed its long term liabilities ($483.2M).


Debt to Equity History and Analysis

Debt Level: ROIV has more cash than its total debt.

Reducing Debt: Insufficient data to determine if ROIV's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: ROIV's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if ROIV's interest payments on its debt are well covered by EBIT.


Balance Sheet


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.